A Phase 3 interventional study of TPS-Select and Pharmacologic Pain Management in Postsurgical Pain Management, Postsurgical Pain, Chronic and Opioid Use After Surgery, sponsored by University of California, San Francisco. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by University of California, San Francisco · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing oxycodone in Pain, Postoperative — 5 open to participants now, 7 under way, 1 of them phase 3. Oxycodone · Pain, Postoperative.
Among the 32 studies testing oxycodone in Pain, Postoperative, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2026, is one of 4 in phase 3, and was the 31st registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →5 of the 32 studies testing oxycodone in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:
Tianjin First Central Hospital · Sites in China
Ages 18–80
Cedars-Sinai Medical Center · Sites in United States
Ages 18+ · Women only
Murdoch Childrens Research Institute · Sites in Australia
Ages 6–18
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 4 · Phase 4 18
First in 2005; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 474 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 126 across the 32 interventional studies. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 32 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
17 studies in Pain, Postoperative by University of California, San Francisco: 4 open now, 5 under way, 1 of them phase 3. Of 12 finished, 6 (50%) have results posted.
Among the 17 studies in Pain, Postoperative by University of California, San Francisco, this one is the 3rd largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 3, and was the 16th registered.
University of California, San Francisco’s Pain, Postoperative studies by the year they started, since 2003.
3 of the studies testing oxycodone in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05548582Johns Hopkins UniversityReduced Opioid Prescription After Laparoscopic Hysterectomy | 2026-12-31 |
| NCT06338865Cedars-Sinai Medical CenterShort Title: Standard vs. Lower Pressure Pneumoperitoneum | 2027-04 |
| NCT03105518Brigham and Women's HospitalPredictors of Postoperative Pain Following Oocyte Retrieval for Assisted Reproduction | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing oxycodone in Pain, Postoperative, from their registry updates:
Among University of California, San Francisco’s 17 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether a pain-management program called a Transitional Pain Service can help prevent long-term pain and reduce opioid needs after surgery in adult surgical patients who may be at higher risk for developing persistent pain. The main questions this trial aims to answer are: 1) Does the Transitional Pain Service help high-risk surgical patients manage pain better after surgery? 2) Can a computer tool (an algorithm) improve screening of patients for long-lasting pain after surgery? The investigators will compare patients who continue with their usual care to patients who receive support from the Transitional Pain Service to see if the program leads to better pain control and lower opioid use. Participants will share information about their pain levels and the pain-relief treatments they are using before and after surgery so researchers can better understand how the program affects recovery. Patients assigned to the Transitional Pain Service will also be offered additional coordinated support before and after their surgery to help optimize their pain control and overall recovery.
The criteria were revised on the registry on Oct 9, 2026. See what changed
Patients may take part in this study if they:
Patients cannot take part if they:
A patient who has already joined may be removed from the study if they:
Patients may remain enrolled but their data may not be used in the main study results if they experience:
Patients assigned to the Transitional Pain Service group will receive extra support before and after surgery to help with pain and recovery. This may include educational videos, meetings with a pain pharmacist for safe medication use and tapering, mental health screening with referrals to supportive resources, and physical therapy. Patients may also be offered pain-relief procedures or treatments such as nerve blocks, injections, imaging, or other outpatient therapies provided by pain specialists. These services are meant to support recovery, and patients may choose how much to participate while remaining in the study even if all activities are not completed.
Device: TPS-Select · Drug: Pharmacologic Pain Management · Procedure: Interventional Pain Procedures · Behavioral: Psychological Management and Pain Education · Behavioral: Physical Therapy
In this arm, patients will receive usual surgical care. However, patients will still complete the questionnaires to measure their pain, opioid use, and recovery.
TPS-Select is a computer-based tool that helps the research team identify patients who may be eligible for this study. It uses information that already exists in the medical record at the time a surgery is scheduled to estimate the chance of developing ongoing pain after surgery. This information can include details about the planned surgery, prior medical conditions, past surgeries, and previous use of pain medications. The tool runs automatically and is used only to help the research team decide whom to contact about possible participation in the study. The risk estimate created by this tool is not added to the medical record and is not seen by the patient's care team. Only approved members of the research team can see this information through a secure research system.
A pharmacist will meet with patients as part of the Transitional Pain Service before and after surgery. During this visit, the pharmacist will work with patients to create a personalized pain management plan, using the medications stated in this intervention to help safely and effectively control pain. This will guide patients on the proper use of opioid analgesics and non-opioid analgesics, including acetaminophen, non-steroid anti-inflammatory drugs, gabapentinoids, and topical medications to manage surgical pain.
Also known as: Oxycodone Hydrochloride, Hydrocodone Bitartrate and Acetaminophen, Morphine Sulfate, Methadone Hydrochloride, Buprenorphine, Gabapentin, Duloxetine Hydrochloride, Pregabalin, Amitriptyline Hydrochloride, Nortriptyline Hydrochloride, Hydromorphone, Venlafaxine, Ketamine, Clonidine, Suzetrigine, Baclofen, Tizanidine, Methocarbamol, Cyclobenzaprine, Ketorolac, Celecoxib, Naproxen, Meloxicam, Ibuprofen, Acetaminophen, Alpha-Lipoic Acid
If a patient has significant pain after their surgery, the care team may evaluate the patient for additional pain-relief options, such as the interventional pain procedures listed above. Local numbing medication or imaging studies may also be used to ensure the treatment is safe and appropriate. All anesthesiologists on the pain service are specially trained to perform these procedures. Only approved procedures will be offered, along with any imaging needed for evaluation.
Also known as: Epidural Steroid Injection, Acupuncture, Trigger Point Injection, Peripheral Nerve Block, Joint Injection, Radiofrequency Ablation
Patients will be asked to complete short online pain education modules to help set expectations and prepare for pain after surgery. These materials are available at https://www.transitionalpainservice.ca/learn. Each patient will also be screened for mood-related concerns, including symptoms of depression, using a brief questionnaire. If a patient has significant symptoms of depression, they may be referred to a pain psychologist and, if needed, a UCSF psychiatrist for additional support. These visits may include proven approaches such as cognitive behavioral therapy, acceptance and commitment therapy, and mindfulness-based strategies to help patients manage pain, cope with stress, and improve daily functioning. Patients with milder symptoms may be referred to group-based pain psychology sessions led by a pain psychologist.
Patients will be assessed for their physical function and ability to carry out daily activities. If a patient has difficulty with mobility, strength, or endurance, they may be referred to physical or occupational therapy before surgery to help improve overall conditioning. Pre-surgery therapy may include exercises to strengthen the core, arms, and legs, improve balance, and build stamina, as well as an overall fitness assessment. Referrals will only be made if it is safe for the patient to participate, and standard safety checks-such as heart health and fall risk-will be completed beforehand. All therapy will be provided by a licensed physical therapist using established, evidence-based treatment plans.
Presence of Chronic Post-Surgical Pain
This outcome measures how many patients in each group (Standard of Care vs. Transitional Pain Service) have chronic post-surgical pain 90 days after date of surgery. Chronic post-surgical pain refers to worsening pain in a preoperative pain region or the development of pain in a new region.
Time frame: 90 days after date of surgery
Opioid Use After Surgery
This measures the amount of opioid medication patients are using after surgery, recorded as morphine milligram equivalents (MMEs). Average MMEs will be compared between groups to see whether the program helps reduce opioid needs.
Time frame: 30, 90, and 180 days after discharge from hospital
Pain Levels After Surgery
This outcome looks at patients' reported pain magnitude and pain interference scores over time. The study will compare average pain levels between the two groups to understand how the program affects recovery.
Time frame: 30, 90, and 180 days after discharge from the hospital
Healthcare Costs
This measures costs to the hospital related to pain care and recovery after surgery. Average costs will be compared between groups to evaluate whether the Transitional Pain Service may reduce overall costs.
Time frame: 30, 90, and 180 days after discharge from the hospital
Pain in Surgical Region
This outcome mreasures patient-reported presence of pain localized to the surgical site.
Time frame: 30 Days, 90 Days, 180 Days
Plan to share: No — Individual participant data will not be shared with outside researchers because the information collected in this study includes sensitive health details that could pose privacy risks if shared. Although all data are protected and stored securely, sharing IPD outside the study team may increase the chance of re-identification. To protect patient privacy, only summarized results that do not identify any individual will be shared publicly.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Dec 2028, 26 months later.
Of 124 non-industry phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 26 months is above that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Dec 2027 → Dec 2028 and completion Jul 2028 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxycodone
University of California, San Francisco →